LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa.

    Butros, Linda / Boayue, Koh / Mathew, Prasad

    Drug design, development and therapy

    2011  Volume 5, Page(s) 275–282

    Abstract: ... with the advantages offered by the use of a new formulation of recombinant activated factor VII that permits improved ... inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes ... and factors that influence this more timely therapeutic approach are highlighted, together ...

    Abstract Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes in this population, timely administration of bypassing agents continues to be hampered by a number of practical limitations, including the need for refrigerated storage of the agent and its reconstitution at room temperature prior to administration, among others. In this review, the importance of early treatment of bleeds and factors that influence this more timely therapeutic approach are highlighted, together with the advantages offered by the use of a new formulation of recombinant activated factor VII that permits improved storage and portability, potentially optimizing timely bypassing agent administration.
    MeSH term(s) Drug Compounding/methods ; Drug Stability ; Drug Storage ; Factor VIIa/administration & dosage ; Factor VIIa/therapeutic use ; Hemophilia A/drug therapy ; Hemophilia A/physiopathology ; Humans ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/therapeutic use ; Temperature ; Time Factors
    Chemical Substances Recombinant Proteins ; recombinant FVIIa (AC71R787OV) ; Factor VIIa (EC 3.4.21.21)
    Language English
    Publishing date 2011-05-12
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S17722
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors

    Butros L / Boayue K / Mathew P

    Drug Design, Development and Therapy, Vol 2011, Iss default, Pp 275-

    a new and practical formulation of recombinant factor VIIa

    2011  Volume 282

    Abstract: ... with the advantages offered by the use of a new formulation of recombinant activated factor VII that permits improved ... inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes ... inhibitors, bleeding, treatment, patients, recombinant factor VIIIa ...

    Abstract Linda Butros, Koh Boayue, Prasad MathewThe University of New Mexico, Albuquerque, New Mexico, USAAbstract: Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes in this population, timely administration of bypassing agents continues to be hampered by a number of practical limitations, including the need for refrigerated storage of the agent and its reconstitution at room temperature prior to administration, among others. In this review, the importance of early treatment of bleeds and factors that influence this more timely therapeutic approach are highlighted, together with the advantages offered by the use of a new formulation of recombinant activated factor VII that permits improved storage and portability, potentially optimizing timely bypassing agent administration.Keywords: hemophilia, inhibitors, bleeding, treatment, patients, recombinant factor VIIIa
    Keywords Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Therapeutics. Pharmacology ; RM1-950 ; DOAJ:Therapeutics
    Subject code 306
    Language English
    Publishing date 2011-05-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top